Orthofix Medical Inc. (NASDAQ:OFIX) CEO Sells $157,739.42 in Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,203 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $17.14, for a total value of $157,739.42. Following the completion of the sale, the chief executive officer now owns 124,151 shares in the company, valued at approximately $2,127,948.14. This represents a 6.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 10th, Massimo Calafiore sold 10,078 shares of Orthofix Medical stock. The stock was sold at an average price of $16.83, for a total value of $169,612.74.

Orthofix Medical Trading Up 2.5 %

Shares of NASDAQ:OFIX opened at $17.94 on Thursday. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The firm has a market capitalization of $685.56 million, a price-to-earnings ratio of -5.73 and a beta of 1.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The business’s 50 day moving average price is $18.16 and its 200-day moving average price is $16.76.

Analyst Ratings Changes

Several research firms have commented on OFIX. Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. Roth Mkm restated a “buy” rating and issued a $22.00 price objective (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Orthofix Medical presently has an average rating of “Moderate Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in OFIX. Paradigm Capital Management Inc. NY lifted its position in shares of Orthofix Medical by 31.3% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after buying an additional 609,137 shares in the last quarter. Engine Capital Management LP lifted its holdings in Orthofix Medical by 11.0% in the 2nd quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock valued at $44,668,000 after purchasing an additional 333,364 shares in the last quarter. Marshall Wace LLP purchased a new position in Orthofix Medical in the 2nd quarter valued at $2,193,000. HighVista Strategies LLC purchased a new position in Orthofix Medical in the 3rd quarter valued at $1,689,000. Finally, JPMorgan Chase & Co. lifted its holdings in Orthofix Medical by 480.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company’s stock valued at $1,318,000 after purchasing an additional 69,848 shares in the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.